EMA Authorised: Xolair (omalizumab) — Novartis Europharm Limited

View source ↗

Summary

EMA has authorised Xolair (omalizumab) for indications including asthma, urticaria, and rhinitis, under the MAH Novartis Europharm Limited.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Rhinitis
• Urticaria

Drugs mentioned

• Xolair (omalizumab)

Snippet

Status: Authorised. Therapeutic area: Asthma;Urticaria;Rhinitis. MAH: Novartis Europharm Limited. Decision date: 05/06/2026